(CDLX) Cardlytics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14161W1053

CDLX: Advertising, Analytics, Data, Marketing, Platform

Cardlytics, Inc. (NASDAQ:CDLX) is a leading provider of advertising and customer data platforms, operating primarily in the United States and the United Kingdom. The company’s core offering includes the Cardlytics platform, a proprietary native bank advertising channel that connects marketers with consumers through partnerships with financial institutions. This platform leverages digital channels such as online banking, mobile applications, email, and real-time notifications to deliver targeted advertisements. Additionally, the Bridg platform serves as a customer data platform that utilizes point-of-sale data to enable advanced analytics, targeted loyalty marketing, and measurable marketing impact analysis. Founded in 2008 and headquartered in Atlanta, Georgia, Cardlytics has established itself as a key player in the advertising technology space. Web URL: https://www.cardlytics.com

From a technical perspective, CDLX is showing a declining trend, with its SMA 20 and SMA 50 below the SMA 200, indicating bearish momentum. The stock is trading at $2.44 with an average volume of 884,119 shares over the past 20 days. The ATR of 0.27 suggests moderate volatility. On the fundamental side, the company has a market cap of $136.71 million, with a price-to-book ratio of 2.16 and a price-to-sales ratio of 0.47, indicating a potentially undervalued stock relative to its peers.

3-Month Forecast (Based on Technical and Fundamental Data): - Technical Outlook: CDLX is expected to remain under pressure as the SMA 20 and SMA 50 continue to trend below the SMA 200. Support levels may be tested near $2.00, with resistance at $3.50. The ATR of 0.27 suggests that price fluctuations will remain moderate. - Fundamental Outlook: The company’s focus on enhancing its customer data platform (Bridg) and expanding its financial institution partnerships could drive incremental revenue growth. However, the absence of positive P/E ratios and the lack of return on equity (RoE) may weigh on investor sentiment. Overall, the stock is likely to trade in a range-bound manner with limited upside potential in the near term.

Additional Sources for CDLX Stock

CDLX Stock Overview

Market Cap in USD 129m
Sector Communication Services
Industry Advertising Agencies
GiC Sub-Industry Advertising
IPO / Inception 2018-02-09

CDLX Stock Ratings

Growth 5y -91.3%
Fundamental -16.4%
Dividend 0.0%
Rel. Strength Industry -84.3
Analysts 2.83/5
Fair Price Momentum 1.31 USD
Fair Price DCF -

CDLX Dividends

No Dividends Paid

CDLX Growth Ratios

Growth Correlation 3m -81.6%
Growth Correlation 12m -87.1%
Growth Correlation 5y -83.4%
CAGR 5y -43.65%
CAGR/Max DD 5y -0.44
Sharpe Ratio 12m -0.25
Alpha -88.52
Beta 2.23
Volatility 115.52%
Current Volume 2577.4k
Average Volume 20d 1052k
What is the price of CDLX stocks?
As of March 18, 2025, the stock is trading at USD 2.47 with a total of 2,577,423 shares traded.
Over the past week, the price has changed by +36.46%, over one month by -26.71%, over three months by -34.48% and over the past year by -81.09%.
Is Cardlytics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Cardlytics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -16.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDLX as of March 2025 is 1.31. This means that CDLX is currently overvalued and has a potential downside of -46.96%.
Is CDLX a buy, sell or hold?
Cardlytics has received a consensus analysts rating of 2.83. Therefor, it is recommend to hold CDLX.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecast for CDLX stock price target?
According to ValueRays Forecast Model, CDLX Cardlytics will be worth about 1.5 in March 2026. The stock is currently trading at 2.47. This means that the stock has a potential downside of -41.3%.
Issuer Forecast Upside
Wallstreet Target Price 3.3 33.6%
Analysts Target Price 4.4 78.1%
ValueRay Target Price 1.5 -41.3%